Bliss GVS Pharma (506197) Stock Overview
Engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
506197 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bliss GVS Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹172.15 |
| 52 Week High | ₹195.85 |
| 52 Week Low | ₹105.05 |
| Beta | 0.93 |
| 1 Month Change | 7.53% |
| 3 Month Change | 13.11% |
| 1 Year Change | 6.56% |
| 3 Year Change | 135.50% |
| 5 Year Change | -11.81% |
| Change since IPO | 67,552.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506197 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.7% | -1.8% | 0.02% |
| 1Y | 6.6% | -2.8% | 4.1% |
Return vs Industry: 506197 exceeded the Indian Pharmaceuticals industry which returned -2.8% over the past year.
Return vs Market: 506197 exceeded the Indian Market which returned 4% over the past year.
Price Volatility
| 506197 volatility | |
|---|---|
| 506197 Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.4% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: 506197's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 506197's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 966 | Shibroor Kamath | www.blissgvs.com |
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, shampoo, soaps, sprays, and vaginal washes.
Bliss GVS Pharma Limited Fundamentals Summary
| 506197 fundamental statistics | |
|---|---|
| Market cap | ₹18.21b |
| Earnings (TTM) | ₹1.10b |
| Revenue (TTM) | ₹8.60b |
Is 506197 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506197 income statement (TTM) | |
|---|---|
| Revenue | ₹8.60b |
| Cost of Revenue | ₹4.40b |
| Gross Profit | ₹4.20b |
| Other Expenses | ₹3.10b |
| Earnings | ₹1.10b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.36 |
| Gross Margin | 48.81% |
| Net Profit Margin | 12.74% |
| Debt/Equity Ratio | 3.1% |
How did 506197 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/17 12:43 |
| End of Day Share Price | 2026/01/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bliss GVS Pharma Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |
| Anil Burra | FirstCall Research |